AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy
Recruiting now
Conditions studied: Hypertrophic Cardiomyopathy (HCM), Left Ventricular Hypertrophy
In brief
By harnessing artificial intelligence to decode the 12-lead electrocardiogram, the project will enable precise ECG-based phenotyping of hypertrophic cardiomyopathy-accurately classifying septal, apical, and other morphologic subtypes-while simultaneously differentiating HCM from hypertensive heart disease, aortic stenosis, and other phenocopy disorders.
Key facts
- Study ID
- NCT07263204
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- People needed
- 15000
- Starts
- 2025-01-01
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2025-12-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Adults aged ≥ 18 years.
- HCM cohort: Adults diagnosed with hypertrophic cardiomyopathy in accordance with the *2023 Chinese Guidelines for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy in Adults*.
- HCM phenocopy cohort: Adults with an LV wall thickness ≥ 13 mm at any site on echocardiography.
- Healthy-control cohort: Adults with no history of cardiac disease and no evidence of myocardial hypertrophy on echocardiography.
You may not qualify if…
- Patients from whom analyzable ECG data cannot be obtained.
Where it is running
- Second Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou, Zhejiang, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.